Raltegravir versus efavirenz regimens in treatment-naive HIV-1–infected patients: 96-week efficacy, durability, subgroup, safety, and metabolic analyses

JL Lennox, E DeJesus, DS Berger… - JAIDS Journal of …, 2010 - journals.lww.com
Background: We analyzed the 96-week results in the overall population and in prespecified
subgroups from the ongoing STARTMRK study of treatment-naive HIV-infected patients …
被引用次数：297 相关文章

Raltegravir versus Efavirenz regimens in treatment-naive HIV-1-infected patients: 96-week efficacy, durability, subgroup, safety, and metabolic analyses.

JL Lennox, E Dejesus, DS Berger… - Journal of Acquired …, 2010 - europepmc.org
Background We analyzed the 96-week results in the overall population and in prespecified
subgroups from the ongoing STARTMRK study of treatment-naive HIV-infected patients …
[HTML] nih.gov

[HTML][HTML] Raltegravir Versus Efavirenz Regimens in Treatment-Naive HIV-1–Infected Patients: 96-Week Efficacy, Durability, Subgroup, Safety, and Metabolic Analyses

JL Lennox, E DeJesus, DS Berger… - Journal of acquired …, 2010 - ncbi.nlm.nih.gov
Background We analyzed the 96-week results in the overall population and in prespecified
subgroups from the ongoing STARTMRK study of treatment-naive HIV-infected patients …

Raltegravir versus Efavirenz regimens in treatment-naive HIV-1-infected patients: 96-week efficacy, durability, subgroup, safety, and metabolic analyses

JL Lennox, E Dejesus, DS Berger, A Lazzarin… - 2010 - pubmed.ncbi.nlm.nih.gov
Background We analyzed the 96-week results in the overall population and in prespecified
subgroups from the ongoing STARTMRK study of treatment-naive HIV-infected patients …
[PDF] academia.edu

[PDF][PDF] Raltegravir Versus Efavirenz Regimens in Treatment-Naive HIV-1–Infected Patients: 96-Week Efficacy, Durability, Subgroup, Safety, and Metabolic Analyses

JL Lennox, E DeJesus, DS Berger, A Lazzarin… - 2010 - academia.edu
Background: We analyzed the 96-week results in the overall population and in prespecified
subgroups from the ongoing STARTMRK study of treatment-naive HIV-infected patients …

Raltegravir versus Efavirenz regimens in treatment-naive HIV-1-infected patients: 96-week efficacy, durability, subgroup, safety, and metabolic analyses.

JL Lennox, E Dejesus, DS Berger… - Journal of Acquired …, 2010 - europepmc.org
Background We analyzed the 96-week results in the overall population and in prespecified
subgroups from the ongoing STARTMRK study of treatment-naive HIV-infected patients …
[PDF] academia.edu

[PDF][PDF] Raltegravir Versus Efavirenz Regimens in Treatment-Naive HIV-1–Infected Patients: 96-Week Efficacy, Durability, Subgroup, Safety, and Metabolic Analyses

JL Lennox, E DeJesus, DS Berger, A Lazzarin… - 2010 - academia.edu
Background: We analyzed the 96-week results in the overall population and in prespecified
subgroups from the ongoing STARTMRK study of treatment-naive HIV-infected patients …

[引用][C] RaltegravirVersus Efavirenz Regimens in Treatment-Naive HIV-1-Infected Patients: 96-Week Efficacy, Durability, Subgroup, Safety, and Metabolic Analyses

JL LENNOX, E DEJESUS… - Journal of …, 2010 - Lippincott Williams & Wilkins